Inicio / Oncología / Abstracts de oncología / Correlation between Skeletal…

Correlation between Skeletal Muscle Mass and Adverse Events of Neoadjuvant Chemotherapy in Patients with Gastric Cancer

0 / 5 (0 votos)
Correlation between Skeletal Muscle Mass and Adverse Events of Neoadjuvant Chemotherapy in Patients with Gastric Cancer

Oncology: International Journal of Cancer Research and Treatment

Fecha de publicación:

DOI: https://doi.org/10.1159/000502613

Autores: Matsuura N., Motoori M., Fujitani K., Nishizawa Y., Komatsu H., Miyazaki Y., Miyazaki S., Tomokuni A., Komori T., Iwase K.

Background: Neoadjuvant chemotherapy (NAC) followed by surgery is a promising treatment strategy for patients with advanced gastric cancer. Severe toxicity associated with the treatment may reduce the dose intensity of chemotherapy, resulting in the effect of chemotherapy being attenuated. Recently, skeletal muscle mass has been reported to be associated with the treatment outcomes of cancer patients. The purpose of this study was to clarify whether pretreatment skeletal muscle mass is a predictor of adverse events as well as the relationship between changes in skeletal muscle mass and adverse events during NAC.

Leer más

Comentarios

Para dejar un comentario antes debes iniciar sesión:

¿No tienes una cuenta?

Regístrate a través de éste enlace.